Canadian Court Upholds Lipitor In Crystal Form

Law360, New York (September 13, 2007, 12:00 AM EDT) -- A federal court in Canada has ruled that Pfizer Inc.’s patent covering the key ingredient in Lipitor would be infringed by Ranbaxy Laboratories Ltd.’s method for developing a generic copy of the cholesterol-lowering drug.

Pfizer, the world’s biggest pharmaceutical company, said Wednesday that the Canadian Federal Court in Toronto barred the Indian generics maker from marketing and selling its generic version of a crystalline form of atorvastatin, the active component in Lipitor, until the Canadian patent expires in July 2016.

However, the court found that Ranbaxy’s...
To view the full article, register now.